-
1
-
-
0014083093
-
Biosynthesis and release of vasopressin
-
Sachs H. Biosynthesis and release of vasopressin. Am J Med. 1967;42:687- 700.
-
(1967)
Am J Med
, vol.42
, pp. 687-700
-
-
Sachs, H.1
-
2
-
-
0001954286
-
The purification and the amino acid content of vasopressin preparations
-
Turner RA, Pierce JG, Du Vigneaud V. The purification and the amino acid content of vasopressin preparations. J Biol Chem. 1951;191:21-28.
-
(1951)
J Biol Chem
, vol.191
, pp. 21-28
-
-
Turner, R.A.1
Pierce, J.G.2
Du Vigneaud, V.3
-
3
-
-
33746875642
-
An investigation of the free amino groups on oxytocin and desulfurized oxytocin preparations
-
Davoll H, Turner RA, Pierce JG, et al. An investigation of the free amino groups on oxytocin and desulfurized oxytocin preparations. J Biol Chem. 1951;193:363-370.
-
(1951)
J Biol Chem
, vol.193
, pp. 363-370
-
-
Davoll, H.1
Turner, R.A.2
Pierce, J.G.3
-
4
-
-
0024801647
-
Discovery, development, and some uses of vaso-pressin and oxytocin antagonists
-
Manning M, Sawyer W. Discovery, development, and some uses of vaso-pressin and oxytocin antagonists. J Lab Clin Med. 1989;114:617-632.
-
(1989)
J Lab Clin Med
, vol.114
, pp. 617-632
-
-
Manning, M.1
Sawyer, W.2
-
5
-
-
67649987273
-
Vasopressin and vasopressin-receptor antagonists in the treatment of cardiovascular disease
-
Frishman WH, Sonnenblick EH, Sica DA, eds, 2nd ed. New York, NY: McGraw Hill
-
Frishman WH, Klapholz M, Acharya N, et al. Vasopressin and vasopressin-receptor antagonists in the treatment of cardiovascular disease. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Pharmacotherapeutics. 2nd ed. New York, NY: McGraw Hill. 2003:601-616.
-
(2003)
Cardiovascular Pharmacotherapeutics
, pp. 601-616
-
-
Frishman, W.H.1
Klapholz, M.2
Acharya, N.3
-
6
-
-
0028134886
-
Cloning and characterization of the human V3 pituitary vasopressin receptors
-
DeKeyzer Y, Auzan C, Lenne F, et al. Cloning and characterization of the human V3 pituitary vasopressin receptors. FEBS Lett. 1994;345:215-220.
-
(1994)
FEBS Lett
, vol.345
, pp. 215-220
-
-
DeKeyzer, Y.1
Auzan, C.2
Lenne, F.3
-
7
-
-
0027270809
-
Renal and central vasopressin receptors: Immunocytochemical localization
-
Fahrenholz F, Jurzak M, Gerstberger R, et al. Renal and central vasopressin receptors: immunocytochemical localization. Ann NY Acad Sci. 1993;689: 194-206.
-
(1993)
Ann NY Acad Sci
, vol.689
, pp. 194-206
-
-
Fahrenholz, F.1
Jurzak, M.2
Gerstberger, R.3
-
8
-
-
0021743563
-
The anterior wall of the third cerebral ventricle and homeostatic responses to dehydration
-
McKinley MJ, Congiu M, Denton DA, et al. The anterior wall of the third cerebral ventricle and homeostatic responses to dehydration. J Physiol-Paris. 1984;79:421-427.
-
(1984)
J Physiol-Paris
, vol.79
, pp. 421-427
-
-
McKinley, M.J.1
Congiu, M.2
Denton, D.A.3
-
9
-
-
0025977407
-
The role of arginine vasopressin for pineal melatonin synthesis in the rat: Involvement of vasopressinergic recep-tors
-
Stehle J, Reuss S, Riemann R, et al. The role of arginine vasopressin for pineal melatonin synthesis in the rat: involvement of vasopressinergic recep-tors. Neurosci Lett. 1991;123:131-134.
-
(1991)
Neurosci Lett
, vol.123
, pp. 131-134
-
-
Stehle, J.1
Reuss, S.2
Riemann, R.3
-
10
-
-
0024361515
-
Criteria for establishment of a physiological role for brain peptides. A case in point: The role of vasopressin in thermoregulation during fever and antipyresis
-
Kasting NW. Criteria for establishment of a physiological role for brain peptides. A case in point: the role of vasopressin in thermoregulation during fever and antipyresis. Brain Res Rev. 1989;14:143-153.
-
(1989)
Brain Res Rev
, vol.14
, pp. 143-153
-
-
Kasting, N.W.1
-
11
-
-
0021683051
-
Hypothermia induced by centrally adminis- tered vasopressin in rats: A structure-activity study
-
Meisenberg G, Simmons WH. Hypothermia induced by centrally adminis- tered vasopressin in rats: a structure-activity study. Neuropharmacol. 1984; 23:1195-1200.
-
(1984)
Neuropharmacol
, vol.23
, pp. 1195-1200
-
-
Meisenberg, G.1
Simmons, W.H.2
-
12
-
-
0024313636
-
Stress selectively activates the vasopressin-containing subset of corticotropin-releasing hormone neurons
-
Whitnall MH. Stress selectively activates the vasopressin-containing subset of corticotropin-releasing hormone neurons. Neuroendocrin. 1989;50:702-707.
-
(1989)
Neuroendocrin
, vol.50
, pp. 702-707
-
-
Whitnall, M.H.1
-
13
-
-
0022587582
-
Vasopressin and oxytocin: Hypothalamic modulators of the stress response: a review
-
Gibbs DM. Vasopressin and oxytocin: hypothalamic modulators of the stress response: a review. Psychoneuroendocrinol. 1986;11:131-139.
-
(1986)
Psychoneuroendocrinol
, vol.11
, pp. 131-139
-
-
Gibbs, D.M.1
-
14
-
-
0027402459
-
Differential effects of centrally injected AVP on heart rate, core temperature, and behavior in rats
-
Diamant M, DeWied D. Differential effects of centrally injected AVP on heart rate, core temperature, and behavior in rats. Am J Physiol. 1993;264: R51-R61.
-
(1993)
Am J Physiol
, vol.264
-
-
Diamant, M.1
DeWied, D.2
-
17
-
-
0019379071
-
Relative contributions of arginine vasopressin and angiotensin II to maintenance of systemic arterial pressure in the anaesthetized water deprived rat
-
Andrews CE, Brenner BM. Relative contributions of arginine vasopressin and angiotensin II to maintenance of systemic arterial pressure in the anaesthetized water deprived rat. Circ Res. 1981;48:254-258.
-
(1981)
Circ Res
, vol.48
, pp. 254-258
-
-
Andrews, C.E.1
Brenner, B.M.2
-
18
-
-
0020858968
-
Contribution of vasopressin to the maintenance of blood pressure during dehydration
-
Woods RL, Johnston CI. Contribution of vasopressin to the maintenance of blood pressure during dehydration. Am J Physiol. 1983;245(5 Pt 1):F615-F621.
-
(1983)
Am J Physiol
, vol.245
, Issue.5 PART 1
-
-
Woods, R.L.1
Johnston, C.I.2
-
19
-
-
0014883371
-
Intestinal vasoconstriction after hemorrhage: Roles of vasopressin and angiotensin
-
McNeill JR, Stark RD, Greenway CV. Intestinal vasoconstriction after hemorrhage: roles of vasopressin and angiotensin. Am J Physiol. 1970;219:1342-1347.
-
(1970)
Am J Physiol
, vol.219
, pp. 1342-1347
-
-
McNeill, J.R.1
Stark, R.D.2
Greenway, C.V.3
-
20
-
-
0020028964
-
Role of vasopressin in abnormal water excretion in cirrhotic patients
-
Bichet D, Szatalowicz V, Chaimovitz C, et al. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med. 1982;96:413-417.
-
(1982)
Ann Intern Med
, vol.96
, pp. 413-417
-
-
Bichet, D.1
Szatalowicz, V.2
Chaimovitz, C.3
-
21
-
-
0028286789
-
Therapeutic efficacy of the non-peptide AVP antagonist OPC 31260 in cirrhotic rats
-
Tsuboi Y, Ishikawa S, Fujisawa G, et al. Therapeutic efficacy of the non-peptide AVP antagonist OPC 31260 in cirrhotic rats. Kidney Int. 1994;46: 237-244.
-
(1994)
Kidney Int
, vol.46
, pp. 237-244
-
-
Tsuboi, Y.1
Ishikawa, S.2
Fujisawa, G.3
-
22
-
-
0023624247
-
Receptors mediating the CRH effects of vasopressin and oxytocin
-
Antoni FA. Receptors mediating the CRH effects of vasopressin and oxytocin. Ann NY Acad Sci. 1987;512:195-204.
-
(1987)
Ann NY Acad Sci
, vol.512
, pp. 195-204
-
-
Antoni, F.A.1
-
23
-
-
0021955473
-
A novel type of vasopressin receptor on anterior pituitary corticotrophs
-
Baertschi AJ, Friedli M. A novel type of vasopressin receptor on anterior pituitary corticotrophs. Endocrinol. 1985;116:499-502.
-
(1985)
Endocrinol
, vol.116
, pp. 499-502
-
-
Baertschi, A.J.1
Friedli, M.2
-
24
-
-
0014400427
-
Renal adenyl cyclase: Anatomically separate sites for parathyroid hormone and vasopressin
-
Chase LR, Aurbach GD. Renal adenyl cyclase: anatomically separate sites for parathyroid hormone and vasopressin. Science. 1968;159:545-547.
-
(1968)
Science
, vol.159
, pp. 545-547
-
-
Chase, L.R.1
Aurbach, G.D.2
-
25
-
-
0017752156
-
Rapid stimulation by vasopressin and adrenaline of inorganic phosphate incorporation into phosphatidyl inositol in isolated hepatocytes
-
Kirk CJ, Verrinder TR, Hems DA. Rapid stimulation by vasopressin and adrenaline of inorganic phosphate incorporation into phosphatidyl inositol in isolated hepatocytes. FEBS Lett. 1977;83:267-271.
-
(1977)
FEBS Lett
, vol.83
, pp. 267-271
-
-
Kirk, C.J.1
Verrinder, T.R.2
Hems, D.A.3
-
26
-
-
0018253517
-
Structural requirements for activation of vasopressin-sensitive adenylate cyclase, hormone binding, and anti-diuretic actions: Effects of highly potent analogues and competitive inhibitors
-
Butlen D, Guillon G, Rajerison RM, et al. Structural requirements for activation of vasopressin-sensitive adenylate cyclase, hormone binding, and anti-diuretic actions: effects of highly potent analogues and competitive inhibitors. Molec Pharmacol. 1978;14:1006-1017.
-
(1978)
Molec Pharmacol
, vol.14
, pp. 1006-1017
-
-
Butlen, D.1
Guillon, G.2
Rajerison, R.M.3
-
27
-
-
0018666457
-
Hormonal stimulation of phosphatidylino-sitol breakdown with particular reference to the hepatic effects of vasopressin
-
Michell RK, Kirk CJ, Billah MM. Hormonal stimulation of phosphatidylino-sitol breakdown with particular reference to the hepatic effects of vasopressin. Biochem Soc Trans. 1979;7:861-865.
-
(1979)
Biochem Soc Trans
, vol.7
, pp. 861-865
-
-
Michell, R.K.1
Kirk, C.J.2
Billah, M.M.3
-
28
-
-
0022610618
-
Vascular vasopressin receptors mediate phosphatidylinositol turnover and calcium efflux in an established smooth muscle cell line
-
Aiyar N, Nambi P, Stassen FL, et al. Vascular vasopressin receptors mediate phosphatidylinositol turnover and calcium efflux in an established smooth muscle cell line. Life Sci. 1986;39:37-45.
-
(1986)
Life Sci
, vol.39
, pp. 37-45
-
-
Aiyar, N.1
Nambi, P.2
Stassen, F.L.3
-
29
-
-
0021257890
-
Novel ligand specificity of pituitary vasopressin receptors in the rat
-
Antoni FA. Novel ligand specificity of pituitary vasopressin receptors in the rat. Neuroendocrin. 1984;39:186-188.
-
(1984)
Neuroendocrin
, vol.39
, pp. 186-188
-
-
Antoni, F.A.1
-
32
-
-
0022973734
-
Vasopressin-mediated inhibition of atrial natriuretic factor-stimulated cGMP accumulation in an established smooth muscle cell line
-
Nambi P, Whitman M, Gessner G, et al. Vasopressin-mediated inhibition of atrial natriuretic factor-stimulated cGMP accumulation in an established smooth muscle cell line. Proc Natl Acad Sci USA. 1986;83:8492-8495.
-
(1986)
Proc Natl Acad Sci USA
, vol.83
, pp. 8492-8495
-
-
Nambi, P.1
Whitman, M.2
Gessner, G.3
-
34
-
-
0021815931
-
Increase in cytosolic calcium and phosphoinositide metabolism induced by angiotensin II and [arg]vasopressin in vascular smooth muscle cell
-
Nabika T, Velletri PA, Lovenberg W, et al. Increase in cytosolic calcium and phosphoinositide metabolism induced by angiotensin II and [arg]vasopressin in vascular smooth muscle cell. J Biol Chem. 1985;260:4661-4670.
-
(1985)
J Biol Chem
, vol.260
, pp. 4661-4670
-
-
Nabika, T.1
Velletri, P.A.2
Lovenberg, W.3
-
35
-
-
0031405967
-
Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells
-
Tahara A, Tomura Y, Wada K, et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells. J Cardiovasc Pharmacol. 1997;30 759-766.
-
(1997)
J Cardiovasc Pharmacol
, vol.30
, pp. 759-766
-
-
Tahara, A.1
Tomura, Y.2
Wada, K.3
-
36
-
-
0033014807
-
Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells
-
Tahara A, Saito M, Tsukada J, et al. Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells. Eur J Pharmacol. 1999;26:89-94.
-
(1999)
Eur J Pharmacol
, vol.26
, pp. 89-94
-
-
Tahara, A.1
Saito, M.2
Tsukada, J.3
-
37
-
-
0024347882
-
2-agonism in dogs
-
2-agonism in dogs. Am J Physiol. 1989;256:H1621-H1626.
-
(1989)
Am J Physiol
, vol.256
-
-
Liard, J.F.1
-
38
-
-
0026611957
-
1-vascular vasopressin receptors
-
1-vascular vasopressin receptors. Reg Peptides. 1992;38:1-11.
-
(1992)
Reg Peptides
, vol.38
, pp. 1-11
-
-
Thibonnier, M.1
-
39
-
-
0025870505
-
Current understanding of the cellular biology and molecular structure of antidiuretic hormone-stimulated water transport pathway
-
Harris HW Jr, Strange K, Zeidel M. Current understanding of the cellular biology and molecular structure of antidiuretic hormone-stimulated water transport pathway. J Clin Invest. 1991;88:1-8.
-
(1991)
J Clin Invest
, vol.88
, pp. 1-8
-
-
Harris Jr, H.W.1
Strange, K.2
Zeidel, M.3
-
40
-
-
0024415848
-
Vasopressin receptors in human seminal vesicles: Identification, pharmacologic characterization, and comparison with the vasopressin receptors present in the human kidney
-
Maggi M, Baldi E, Genazzani AD, et al. Vasopressin receptors in human seminal vesicles: identification, pharmacologic characterization, and comparison with the vasopressin receptors present in the human kidney. J Androl. 1989;10:393-400.
-
(1989)
J Androl
, vol.10
, pp. 393-400
-
-
Maggi, M.1
Baldi, E.2
Genazzani, A.D.3
-
41
-
-
0028364549
-
Endocytosis of the vasopressin receptor
-
Kumar R. Endocytosis of the vasopressin receptor. Semin Nephrol. 1994;14: 357-367.
-
(1994)
Semin Nephrol
, vol.14
, pp. 357-367
-
-
Kumar, R.1
-
42
-
-
40749135917
-
Acute variceal bleeding: Pharmacological treatment and primary/secondary prophylaxis
-
Dell'Era A, de Franchis R, Iannuzzi F. Acute variceal bleeding: pharmacological treatment and primary/secondary prophylaxis. Best Pract Res Clin Gastroenterol. 2008;22:279-294.
-
(2008)
Best Pract Res Clin Gastroenterol
, vol.22
, pp. 279-294
-
-
Dell'Era, A.1
de Franchis, R.2
Iannuzzi, F.3
-
43
-
-
0021988346
-
Interactions of vasopressin with the area postrema in arterial baroreflex function in conscious rabbits
-
Undesser KP, Hasser EM, Haywood JR, et al. Interactions of vasopressin with the area postrema in arterial baroreflex function in conscious rabbits. Circ Res. 1985;56:410-417.
-
(1985)
Circ Res
, vol.56
, pp. 410-417
-
-
Undesser, K.P.1
Hasser, E.M.2
Haywood, J.R.3
-
44
-
-
0025346650
-
1 receptors in the area postrema
-
1 receptors in the area postrema. Circ Res. 1990;67:265-271.
-
(1990)
Circ Res
, vol.67
, pp. 265-271
-
-
Hasser, E.M.1
Bishop, V.S.2
-
45
-
-
0024463128
-
Central nervous system mechanisms involved in inhibition of renal sympathetic nerve activity induced by arginine vasopressin
-
Suzuki S, Takeshita A, Imaizumi T, et al. Central nervous system mechanisms involved in inhibition of renal sympathetic nerve activity induced by arginine vasopressin. Circ Res. 1989;65:1390-1399.
-
(1989)
Circ Res
, vol.65
, pp. 1390-1399
-
-
Suzuki, S.1
Takeshita, A.2
Imaizumi, T.3
-
46
-
-
0028140156
-
Role of vasopressin in sympathetic response to paraventricular nucleus stimulation in anesthetized rats
-
Malpas SC, Coote JH. Role of vasopressin in sympathetic response to paraventricular nucleus stimulation in anesthetized rats. Am J Physiol. 1994; 266:R228-R236.
-
(1994)
Am J Physiol
, vol.266
-
-
Malpas, S.C.1
Coote, J.H.2
-
47
-
-
0031025550
-
Sex differences in the cardiovascular and renal actions of vasopressin in conscious rats
-
Wang YX, Crofton JT, Share L. Sex differences in the cardiovascular and renal actions of vasopressin in conscious rats. Am J Physiol. 1997;272(1 pt 2):R370-R376.
-
(1997)
Am J Physiol
, vol.272
, Issue.1 PART 2
-
-
Wang, Y.X.1
Crofton, J.T.2
Share, L.3
-
48
-
-
0032553654
-
Sex differences in extracellular and intracellular calcium-mediated vascular reactivity to vasopressin in rat aorta
-
Eatman D, Stallone JN, Rutecki GW, et al. Sex differences in extracellular and intracellular calcium-mediated vascular reactivity to vasopressin in rat aorta. Eur J Pharmacol. 1998;20:207-216.
-
(1998)
Eur J Pharmacol
, vol.20
, pp. 207-216
-
-
Eatman, D.1
Stallone, J.N.2
Rutecki, G.W.3
-
49
-
-
0028155695
-
2-induced vasodilation in dogs
-
2-induced vasodilation in dogs. Am J Physiol. 1994;26:H99-H106.
-
(1994)
Am J Physiol
, vol.26
-
-
Liard, J.F.1
-
50
-
-
0027994386
-
Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: Hyponatremia, hypokalemia, and hypomagnesemia
-
Leier CV, Dei Cas L, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J. 1994;128:254.
-
(1994)
Am Heart J
, vol.128
, pp. 254
-
-
Leier, C.V.1
Dei Cas, L.2
Metra, M.3
-
51
-
-
0025153828
-
Comparison of neuro-endocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)
-
Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuro-endocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729.
-
(1990)
Circulation
, vol.82
, pp. 1724-1729
-
-
Francis, G.S.1
Benedict, C.2
Johnstone, D.E.3
-
52
-
-
0031011283
-
Role of vasopressin in essential hypertension: Racial differences
-
Bakris G, Bursztyn M, Gavras I, et al. Role of vasopressin in essential hypertension: racial differences. J Hyperten. 1997;15:545-550.
-
(1997)
J Hyperten
, vol.15
, pp. 545-550
-
-
Bakris, G.1
Bursztyn, M.2
Gavras, I.3
-
53
-
-
0025880776
-
Role of vasopressin in clinical hypertension and congestive cardiac failure: Interaction with the sympathetic nervous system
-
Gavras H. Role of vasopressin in clinical hypertension and congestive cardiac failure: interaction with the sympathetic nervous system. Clin Chem. 1991; 37(10 Pt 2):1828-1830.
-
(1991)
Clin Chem
, vol.37
, Issue.10 PART 2
, pp. 1828-1830
-
-
Gavras, H.1
-
54
-
-
0028017360
-
Prognostic value of neurohormonal activation in patients with an acute myocardial infarction: Effect of captopril
-
Rouleau JL, Packer M, Moye L, et al. Prognostic value of neurohormonal activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol. 1994;24:583-591.
-
(1994)
J Am Coll Cardiol
, vol.24
, pp. 583-591
-
-
Rouleau, J.L.1
Packer, M.2
Moye, L.3
-
55
-
-
33745712365
-
Water and sodium retention in edematous disorders: Role of vasopressin and aldosterone
-
Schrier RW. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am J Med. 2006;119(suppl 1):S47-S53.
-
(2006)
Am J Med
, vol.119
, Issue.SUPPL. 1
-
-
Schrier, R.W.1
-
56
-
-
0022469780
-
Sequential elimination of pressor mechanisms in severe hypertension in humans
-
Ribeiro A, Mulinari R, Gavras I, et al. Sequential elimination of pressor mechanisms in severe hypertension in humans. Hypertension. 1986;8(Suppl I):I-169.
-
(1986)
Hypertension
, vol.8
, Issue.SUPPL. I
-
-
Ribeiro, A.1
Mulinari, R.2
Gavras, I.3
-
57
-
-
0020652610
-
Role of angiotensin and vasopressin on blood pressure of ganglionic blocked dogs
-
Houck PC, Fiksen-Olsen MJ, Briton SL, et al. Role of angiotensin and vasopressin on blood pressure of ganglionic blocked dogs. Am J Physiol. 1983;244:H115-H120.
-
(1983)
Am J Physiol
, vol.244
-
-
Houck, P.C.1
Fiksen-Olsen, M.J.2
Briton, S.L.3
-
58
-
-
0032988191
-
2 receptor antagonist, in dogs with pacing-induced congestive heart failure
-
2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol. 1999;376:239-246.
-
(1999)
Eur J Pharmacol
, vol.376
, pp. 239-246
-
-
Yatsu, T.1
Tomura, Y.2
Tahara, A.3
-
60
-
-
0022518427
-
The adrenergic system and the release and pressor action of vasopressin
-
Gavras I, Hatinoglou S, Gavras H. The adrenergic system and the release and pressor action of vasopressin. Hypertension. 1986;8(Suppl II):163-167.
-
(1986)
Hypertension
, vol.8
, Issue.SUPPL. II
, pp. 163-167
-
-
Gavras, I.1
Hatinoglou, S.2
Gavras, H.3
-
61
-
-
0028241011
-
Treatment with cilazapril, angioten-sin converting enzyme inhibitor, changes the affinity of arginine vasopressin receptor in the kidney of the spontaneously hypertensive rat
-
Nishida N, Ogura Y, Yamauchi T, et al. Treatment with cilazapril, angioten-sin converting enzyme inhibitor, changes the affinity of arginine vasopressin receptor in the kidney of the spontaneously hypertensive rat. Res Commun Chem Pathol Pharm. 1994;84:143-152.
-
(1994)
Res Commun Chem Pathol Pharm
, vol.84
, pp. 143-152
-
-
Nishida, N.1
Ogura, Y.2
Yamauchi, T.3
-
62
-
-
0018945560
-
The cardiovascular effect of vasopres-sin in relation to its plasma concentration in man and its relevance to high blood pressure
-
Khokhar AM, Slater JDH, Ma J, et al. The cardiovascular effect of vasopres-sin in relation to its plasma concentration in man and its relevance to high blood pressure. Clin Endocrin. 1980;13:259-266.
-
(1980)
Clin Endocrin
, vol.13
, pp. 259-266
-
-
Khokhar, A.M.1
Slater, J.D.H.2
Ma, J.3
-
63
-
-
0019947661
-
Interaction of the sympathetic nervous system with vasopressin and renin in the maintenance of blood pressure
-
Gavras H, Hatzinikolaou P, North WG, et al. Interaction of the sympathetic nervous system with vasopressin and renin in the maintenance of blood pressure. Hypertension. 1982;4:400-405.
-
(1982)
Hypertension
, vol.4
, pp. 400-405
-
-
Gavras, H.1
Hatzinikolaou, P.2
North, W.G.3
-
64
-
-
0042354581
-
Diuretic use, progressive heart failure and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD)
-
Domanski M, Norman J, Pitt B, et al. Diuretic use, progressive heart failure and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll of Cardiol. 2003;42:705-708.
-
(2003)
J Am Coll of Cardiol
, vol.42
, pp. 705-708
-
-
Domanski, M.1
Norman, J.2
Pitt, B.3
-
65
-
-
0344420330
-
Predicting mortality among patients hospitalized for heart failure: Derivation and validation of a clinical model
-
Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581-2587.
-
(2003)
JAMA
, vol.290
, pp. 2581-2587
-
-
Lee, D.S.1
Austin, P.C.2
Rouleau, J.L.3
-
67
-
-
18844423537
-
Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: Results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study
-
Klein L, O'Connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005;111:2454-2460.
-
(2005)
Circulation
, vol.111
, pp. 2454-2460
-
-
Klein, L.1
O'Connor, C.M.2
Leimberger, J.D.3
-
69
-
-
0032240078
-
2-receptor antagonist: Pharmacologic profile and aquaretic effect by single and multiple oral dosing in rats
-
2-receptor antagonist: pharmacologic profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther . 1998;287:860-867.
-
(1998)
J Pharmacol Exp Ther
, vol.287
, pp. 860-867
-
-
Yamamura, Y.1
Nakamura, S.2
Itoh, S.3
-
70
-
-
39749187298
-
2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure
-
2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Biochemical Pharmacol. 2008;75:1322-1330.
-
(2008)
Biochemical Pharmacol
, vol.75
, pp. 1322-1330
-
-
Veeraveedu, P.T.1
Watanabe, K.2
Ma, M.3
-
71
-
-
0033965154
-
2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats
-
2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther. 2000;292:288-294.
-
(2000)
J Pharmacol Exp Ther
, vol.292
, pp. 288-294
-
-
Hirano, T.1
Yoshitaka, Y.2
Nakamura, S.3
-
72
-
-
0037904417
-
2-receptor blockade with tolvaptan in patients with chronic heart failure: Results from a double-blind, randomized trial
-
2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107:2690-2696.
-
(2003)
Circulation
, vol.107
, pp. 2690-2696
-
-
Gheorghiade, M.1
Niazi, I.2
Ouyang, J.3
-
73
-
-
11144355788
-
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial
-
Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963-1971.
-
(2004)
JAMA
, vol.291
, pp. 1963-1971
-
-
Gheorghiade, M.1
Gattis, W.A.2
O'Connor, C.M.3
-
74
-
-
33947719178
-
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials
-
Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332.
-
(2007)
JAMA
, vol.297
, pp. 1332
-
-
Gheorghiade, M.1
Konstam, M.A.2
Burnett Jr, J.C.3
-
75
-
-
33947713810
-
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial
-
Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319.
-
(2007)
JAMA
, vol.297
, pp. 1319
-
-
Konstam, M.A.1
Gheorghiade, M.2
Burnett Jr, J.C.3
-
76
-
-
67649922085
-
Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker
-
September 19, Washington, DC. Recent and Late-Breaking Trials session
-
Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: the ECLIPSE international, multi-center, randomized, placebo-controlled trial. Heart Failure Society of America 2006 Scientific Meeting; September 19, 2007; Washington, DC. Recent and Late-Breaking Trials session.
-
(2007)
patients with symptomatic heart failure and systolic dysfunction: The ECLIPSE international, multi-center, randomized, placebo-controlled trial. Heart Failure Society of America 2006 Scientific Meeting
-
-
Udelson, J.E.1
Orlandi, C.2
Ouyang, J.3
-
78
-
-
0018897308
-
1(ß-mercapto-ß- cyclopentamethyl-eneproprionic acid)2-(O-methyl)tyrosine] argin vasopressin and [1-(ß-mercapto-ß, ß-cyclopenta-methyleneproprionic acid)] argin vasopressin, two highly potent antagonists of the vasopressor response to arginine-vasopressin
-
Kruszynski M, Lammeck B, Manning M, et al. [1(ß-mercapto-ß- cyclopentamethyl-eneproprionic acid)2-(O-methyl)tyrosine] argin vasopressin and [1-(ß-mercapto-ß, ß-cyclopenta-methyleneproprionic acid)] argin vasopressin, two highly potent antagonists of the vasopressor response to arginine-vasopressin J Med Chem. 1980;23:364-368.
-
(1980)
J Med Chem
, vol.23
, pp. 364-368
-
-
Kruszynski, M.1
Lammeck, B.2
Manning, M.3
-
79
-
-
0037823130
-
Vasopressin: A new target for the treatment of heart failure
-
Lee CR, Watkins M, Patteron JH, et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J. 2003;146:9-18.
-
(2003)
Am Heart J
, vol.146
, pp. 9-18
-
-
Lee, C.R.1
Watkins, M.2
Patteron, J.H.3
-
80
-
-
0021276993
-
5Tyr/Et/VAVP on the antidiuretic action of exogenous and endogenous vasopressin
-
5Tyr/Et/VAVP on the antidiuretic action of exogenous and endogenous vasopressin. Acta Endocrinol. 1984;106:52-55.
-
(1984)
Acta Endocrinol
, vol.106
, pp. 52-55
-
-
Laszlo, F.A.1
Csati, S.2
Balaspiri, L.3
-
85
-
-
0035856509
-
2 vasopressin receptor antagonist in patients with advanced heart failure
-
2 vasopressin receptor antagonist in patients with advanced heart failure. Circulation. 2001;104:2417-2423.
-
(2001)
Circulation
, vol.104
, pp. 2417-2423
-
-
Udelson, J.E.1
Smith, W.B.2
Hendrix, G.H.3
-
86
-
-
33646054125
-
2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients
-
2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol. 2006;47:1615-1621.
-
(2006)
J Am Coll Cardiol
, vol.47
, pp. 1615-1621
-
-
Abraham, W.T.1
Shamshirsaz, A.A.2
McFann, K.3
|